A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies

Trial Profile

A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Hmpl 453 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 14 Feb 2017 According to a Hutchison China MediTech Limited media release, first drug dose was administered.
    • 08 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 22 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top